Royal Bank of Canada’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-201,624
| Closed | -$13.7M | – | 8203 |
|
|
2022
Q3 | $13.7M | Sell |
201,624
-216,982
| -52% | -$12M | ﹤0.01% | 1316 |
|
|
2022
Q2 | $13.4M | Buy |
418,606
+66,520
| +19% | +$1.95M | ﹤0.01% | 1366 |
|
|
2022
Q1 | $12.2M | Buy |
352,086
+274,497
| +354% | +$8.21M | ﹤0.01% | 1572 |
|
|
2021
Q4 | $2.27M | Buy |
77,589
+22,596
| +41% | +$700K | ﹤0.01% | 3046 |
|
|
2021
Q3 | $1.4M | Buy |
54,993
+19,076
| +53% | +$561K | ﹤0.01% | 3381 |
|
|
2021
Q2 | $1.26M | Buy |
35,917
+1,017
| +3% | +$39.7K | ﹤0.01% | 3466 |
|
|
2021
Q1 | $1.42M | Sell |
34,900
-133,631
| -79% | -$6.14M | ﹤0.01% | 3288 |
|
|
2020
Q4 | $7.3M | Buy |
168,531
+70,069
| +71% | +$3.45M | ﹤0.01% | 1936 |
|
|
2020
Q3 | $5.43M | Buy |
98,462
+30,788
| +45% | +$1.96M | ﹤0.01% | 1955 |
|
|
2020
Q2 | $4.27M | Buy |
67,674
+8,088
| +14% | +$555K | ﹤0.01% | 2050 |
|
|
2020
Q1 | $3.04M | Buy |
59,586
+15,877
| +36% | +$1.06M | ﹤0.01% | 2156 |
|
|
2019
Q4 | $3.47M | Buy |
43,709
+23,468
| +116% | +$1.39M | ﹤0.01% | 2420 |
|
|
2019
Q3 | $982K | Buy |
20,241
+19,134
| +1,728% | +$997K | ﹤0.01% | 3359 |
|
|
2019
Q2 | $58K | Sell |
1,107
-981
| -47% | -$56.4K | ﹤0.01% | 5199 |
|
|
2019
Q1 | $110K | Sell |
2,088
-383
| -15% | -$18.8K | ﹤0.01% | 4720 |
|
|
2018
Q4 | $101K | Sell |
2,471
-89
| -3% | -$3.33K | ﹤0.01% | 4718 |
|
|
2018
Q3 | $97K | Sell |
2,560
-157,266
| -98% | -$6.97M | ﹤0.01% | 4877 |
|
|
2018
Q2 | $7.22M | Sell |
159,826
-15,287
| -9% | -$696K | ﹤0.01% | 1752 |
|
|
2018
Q1 | $8.46M | Buy |
175,113
+115,746
| +195% | +$6.46M | ﹤0.01% | 1648 |
|
|
2017
Q4 | $2.34M | Buy |
59,367
+55,226
| +1,334% | +$2.06M | ﹤0.01% | 2605 |
|
|
2017
Q3 | $129K | Buy |
4,141
+3,506
| +552% | +$98.6K | ﹤0.01% | 4834 |
|
|
2017
Q2 | $17K | Buy |
635
+198
| +45% | +$5.89K | ﹤0.01% | 5606 |
|
|
2017
Q1 | $16K | Sell |
437
-971
| -69% | -$24.5K | ﹤0.01% | 5748 |
|
|
2016
Q4 | $21K | Buy |
1,408
+743
| +112% | +$13.1K | ﹤0.01% | 5748 |
|
|
2016
Q3 | $15K | Hold |
665
| – | – | ﹤0.01% | 5658 |
|
|
2016
Q2 | $11K | Hold |
665
| – | – | ﹤0.01% | 5729 |
|
|
2016
Q1 | $11K | Buy |
+665
| New | +$11.8K | ﹤0.01% | 5707 |
|
|
2015
Q4 | – | Sell |
-400
| Closed | -$17K | – | 6900 |
|
|
2015
Q3 | $17K | Buy |
+400
| New | +$18.9K | ﹤0.01% | 5642 |
|
Other funds holding GBT
Royal Bank of Canada's GBT Position: Q4 2022 in Review
Royal Bank of Canada sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 201,624 shares — an estimated $13.7M sold.
Royal Bank of Canada first reported a position in GBT in Q3 2015 and held it in 28 quarters. The position peaked at $13.7M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Royal Bank of Canada reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Royal Bank of Canada sold 201,624 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $13.7M.
- Royal Bank of Canada first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 28 quarters.
- Royal Bank of Canada's Global Blood Therapeutics, Inc. position peaked at $13.7M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.